The clinical use of bone resorption markers in patients with malignant bone disease

Bone disease is observed in almost 80% of newly diagnosed symptomatic multiple myeloma patients, and spine is the bone site that is more frequently affected by myeloma-induced osteoporosis, osteolyses, or compression fractures. In almost 20% of the cases, spinal cord compression may occur; diagnosis and treatment must be carried out rapidly in order to avoid a permanent sensitive or motor defect. Although whole body skeletal X-ray is considered mandatory for multiple myeloma staging, magnetic resonance imaging is presently considered the most appropriate diagnostic technique for the evaluation of vertebral alterations, as it allows to detect not only the exact morphology of the lesions, but also the pattern of bone marrow infiltration by the disease. Multiple treatment modalities can be used to manage multiple myeloma-related vertebral lesions. Surgery or radiotherapy is mainly employed in case of spinal cord compression, impending fractures, or intractable pain. Percutaneous vertebroplasty or balloon kyphoplasty can reduce local pain in a significant fraction of treated patients, without interfering with subsequent therapeutic programs. Systemic antimyeloma therapy with conventional chemotherapy or, more appropriately, with combinations of conventional chemotherapy and compounds acting on both neoplastic plasma cells and bone marrow microenvironment must be soon initiated in order to reduce bone resorption and, possibly, promote bone formation. Bisphosphonates should also be used in combination with antimyeloma therapy as they reduce bone resorption and prolong patients survival. A multidisciplinary approach is thus needed in order to properly manage spinal involvement in multiple myeloma.

Download Full-text

Serum levels of bone resorption markers are decreased in patients with type 2 diabetes

Acta Diabetologica ◽

10.1007/s00592-011-0347-0 ◽

2011 ◽

Vol 50 (1) ◽

pp. 47-52 ◽

Cited By ~ 32

Author(s):

Rebeca Reyes-García ◽

Pedro Rozas-Moreno ◽

Gema López-Gallardo ◽

Antonia García-Martín ◽

Mariela Varsavsky ◽

...

Keyword(s):

Type 2 Diabetes ◽

Bone Resorption ◽

Serum Levels ◽

Bone Resorption Markers

Download Full-text

Stress Fracture Influences Bone Resorption marker (u-NTX) in Female Long Distance Runners

International Journal of Sports Medicine ◽

10.1055/s-0043-119223 ◽

2017 ◽

Vol 38 (14) ◽

pp. 1070-1075 ◽

Cited By ~ 2

Author(s):

Shimpei Fujita ◽

Keishoku Sakuraba ◽

Atsushi Kubota ◽

Kenta Wakamatsu ◽

Natsue Koikawa

Keyword(s):

Bone Resorption ◽

Stress Fracture ◽

Premenopausal Women ◽

Mean Value ◽

Bone Resorption Marker ◽

Distance Runners ◽

Survey Period ◽

Long Distance ◽

Bone Resorption Markers ◽

The Mean

AbstractIn this study, we aim to clarify the influence based on bone resorption markers at onset of stress fracture. Also, we will clarify the state of the bone resorption markers of female long distance runners who have a history of stress fracture and also ones who routinely practices running long distances. Participants comprised 19 female long distance athletes. The survey period was 2011–2014, and we measured u-NTX as a bone resorption marker at least twice a year, taking the mean±SD of the periodic measured values without stress fracture as the mean value. Measurements were collected sample when stress fractures developed. 132 u-NTX measurements were taken from 19 participants. As a result, the average was 41.03±12.31 nmolBCE/mmolCRE (Q1: 33.15, Q2: 40.55, Q3: 47.95). In six of the 19 participants, u-NTX could be measured following a stress fracture. The mean value of u-NTX for those participants was 40.16±9.10 nmolBCE/mmolCRE, increasing to 64.08±16.07 nmolBCE/mmol CRE with the stress fracture (p<0.01). The findings showed that, in adult female long distance runners, u-NTX values when there was no stress fracture were within the standard value for mean premenopausal women, but increased when the athletes suffered from a stress fracture.

Download Full-text

Gastrectomy induces negative changes of bone resorption markers and volumetric bone mineral density (VBMD) of lumbar spine in one-year study

Bone ◽

10.1016/j.bone.2012.02.452 ◽

2012 ◽

Vol 50 ◽

pp. S145-S146

Author(s):

W. Krupski⁎ ◽

M.R. Tatara ◽

A. Dabrowski ◽

P. Bury ◽

G. Wallner

Keyword(s):

Bone Mineral Density ◽

Lumbar Spine ◽

Bone Resorption ◽

Bone Mineral ◽

Volumetric Bone Mineral Density ◽

Mineral Density ◽

Bone Resorption Markers ◽

One Year

Download Full-text

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2018-214729 ◽

2019 ◽

Vol 78 (6) ◽

pp. 754-760 ◽

Cited By ~ 14

Author(s):

Sudha Visvanathan ◽

Stefan Daniluk ◽

Rafał Ptaszyński ◽

Ulf Müller-Ladner ◽

Meera Ramanujam ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Bone Resorption ◽

Primary Endpoint ◽

Study Drug ◽

Nuclear Factor Κb ◽

Inadequate Response ◽

Serious Adverse Events ◽

Double Blind ◽

Autoantibody Production ◽

Bone Resorption Markers

ObjectiveTo evaluate the safety, efficacy and therapeutic mechanism of BI 655064, an antagonistic anti-CD40 monoclonal antibody, in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX-IR).MethodsIn total, 67 patients were randomised to receive weekly subcutaneous doses of 120 mg BI 655064 (n=44) or placebo (n=23) for 12 weeks. The primary endpoint was the proportion of patients who achieved 20% improvement in American College of Rheumatology criteria (ACR20) at week 12. Safety was assessed in patients who received at least one dose of study drug.ResultsAt week 12, the primary endpoint was not met, with 68.2% of patients treated with BI 655064 achieving an ACR20 vs 45.5% with placebo (p=0.064); using Bayesian analysis, the posterior probability of seeing a difference greater than 35% was 42.9%. BI 655064 was associated with greater changes in CD40–CD40L pathway-related markers, including reductions in inflammatory and bone resorption markers (interleukin-6, matrix metalloproteinase-3, receptor activator of nuclear factor-κB ligand), concentration of autoantibodies (immunoglobulin [Ig]G rheumatoid factor [RF], IgM RF, IgA RF) and CD95+ activated B-cell subsets. No serious adverse events (AEs) related to BI 655064 treatment or thromboembolic events occurred; reported AEs were mainly of mild intensity.ConclusionAlthough blockade of the CD40–CD40L pathway with BI 655064 in MTX-IR patients with RA resulted in marked changes in clinical and biological parameters, including reductions in activated B-cells, autoantibody production and inflammatory and bone resorption markers, with a favourable safety profile, clinical efficacy was not demonstrated in this small phase IIa study.Trial registration numberNCT01751776

Download Full-text